View printer-friendly version |
« Back |
December 04, 2013 11:44 a.m. |
![]() |
Teva to Host 2014 Business Outlook Conference Call and Webcast on December 10, 2013 |
![]() |
![]() |
In order to participate, please dial the following numbers (at least 10
minutes before the scheduled start time): A live webcast of the call will also be available on Teva's website at: www.tevapharm.com Please log in at least 10 minutes prior to the conference call in order to download the applicable audio software.
Following the conclusion of the call, a replay of the webcast will be
available within 24 hours on the Company's website. The replay can also
be accessed until About Teva
Teva's Safe Harbor Statement under the
This document contains forward-looking statements, which express the
current beliefs and expectations of management. Such statements involve
a number of known and unknown risks and uncertainties that could cause
our future results, performance or achievements to differ significantly
from the results, performance or achievements expressed or implied by
such forward-looking statements. Important factors that could cause or
contribute to such differences include risks relating to: the ability to
reduce operating expenses to the extent and during the timeframe
intended by our cost restructuring program; our ability to develop and
commercialize additional pharmaceutical products, including our ability
to develop, manufacture, market and sell biopharmaceutical products,
competition for our innovative medicines, especially COPAXONE®
(including competition from innovative orally-administered alternatives,
as well as from potential purported generic equivalents), competition
for our generic products (including from other pharmaceutical companies
and as a result of increased governmental pricing pressures),
competition for our specialty pharmaceutical businesses, our ability to
achieve expected results through our specialty, including innovative,
R&D efforts, the effectiveness of our patents and other protections for
innovative products, decreasing opportunities to obtain U.S. market
exclusivity for significant new generic products, our ability to
identify, consummate and successfully integrate acquisitions and license
products, our ability to reduce operating expenses to the extent and
during the timeframe intended by our cost restructuring program,
uncertainties relating to the replacement of and transition to a new
President & Chief Executive Officer, the effects of increased leverage
as a result of recent acquisitions, the extent to which any
manufacturing or quality control problems damage our reputation for high
quality production and require costly remediation, our potential
exposure to product liability claims to the extent not covered by
insurance, increased government scrutiny in both the U.S. and
Source:
Teva Pharmaceutical Industries Ltd.
|